Treatment of apolipoprotein-a1 related diseases by inhibition of natural antisense transcript to apolipoprotein-a1

Treatment of apolipoprotein-a1 related diseases by inhibition of natural antisense transcript to apolipoprotein-a1

  • CN 102,239,260 B
  • Filed: 10/02/2009
  • Issued: 04/12/2017
  • Est. Priority Date: 10/03/2008
  • Status: Active Grant
First Claim
Patent Images

1. the antisense oligonucleotide of 10-30 nucleotide of length is being prepared for raising Patient cells or group in vivo or in vitroIn knitting with SEQ ID NO:

  • Purposes in 1 ApoA poA1 polynucleotide functions and/or the medicine of expression, whereinThe oligonucleotide natural antisense polynucleotide of ApoA1 genes are had specificity and with the reverse mutual complement of polynucleotide10-30 nucleotide regions there is sequence iden, the polynucleotide are included in SEQ ID NO:

    2 it is described natural10-30 continuous nucleotides in the nucleotide 1-932 of antisense polynucleotides.

View all claims
    ×
    ×

    Thank you for your feedback

    ×
    ×